Company Overview - Shandong Xinhua Medical Equipment Co., Ltd. specializes in the manufacturing and sales of medical devices and pharmaceutical equipment, providing compatible medical services and medical commerce [2] - The company is a leading entity in the Chinese medical device industry, holding several key positions in various associations and has developed innovative products such as the world's first peracetic acid low-temperature sterilizer [2] Financial Performance - For Q1 2025, the company reported revenue of 2.308 billion yuan, a year-on-year decrease of 8.74%, and a net profit of 160 million yuan, down 23.97% compared to the previous year [3] - The company's gross profit margin stood at 23.79% [3] Market Position - As of August 11, the company's stock closed at 18.14 yuan, with a rolling price-to-earnings (PE) ratio of 17.17, marking a new low in 161 days [1] - The average PE ratio for the medical device industry is 56.56, with a median of 39.76, placing Xinhua Medical at the 36th position within the industry [1] Shareholder Information - As of March 31, 2025, the number of shareholders for Xinhua Medical reached 38,959, an increase of 5,308 from the previous count, with an average holding value of 352,800 yuan per shareholder [1]

来源：金融界 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均54.32倍，行业中值38.11倍，新华医疗排 名第33位。 股东方面，截至2025年3月31日，新华医疗股东户数38959户，较上次增加5308户，户均持股市值35.28 万元，户均持股数量2.76万股。 山东新华医疗器械股份有限公司的主营业务是医疗器械、制药装备的制造销售，提供适配的医疗服务与 医疗商贸。公司的主要产品是医疗器械制造产品、制药装备产品、医疗商贸产品、医疗服务。公司是中 国医疗器械行业协会会长单位，中国医学装备协会副理事长单位，感染与控制技术专业委员会理事长单 位，中国放射治疗产业技术创新战略联盟理事长单位，中国制药装备行业协会理事单位，中国医药设备 工程协会理事单位。公司研制开发了全球第一台过氧乙酸低温灭菌器、国内首台高能医用电子直线加速 器等高精尖产品，建成了国内首个智慧化消毒供应中心等行业创新工程，荣获了中国灭菌设备领域第一 张FDA认证证书。公司是国家重点高新技术企业，拥有行业内第一家国家认定企业技术中心，设有"博 士后科研工作站"、"先进医疗设备及器械山东省工程研究中心"等多个省级技术研发平台，每年新增重 点技术创 ...

Group 1 - The core business of the company includes the manufacturing and sales of medical devices and pharmaceutical equipment, as well as providing medical services and trade [2] - The company is a leading entity in the Chinese medical device industry, holding several key positions in industry associations and has developed innovative products such as the world's first peracetic acid low-temperature sterilizer [2] - As of the first quarter of 2025, the company reported a revenue of 2.308 billion yuan, a year-on-year decrease of 8.74%, and a net profit of 160 million yuan, down 23.97% [3] Group 2 - The company's current rolling price-to-earnings (PE) ratio is 14.22, significantly lower than the industry average of 49.10 and the industry median of 36.43 [1][3] - The total market capitalization of the company is 9.118 billion yuan, ranking it 33rd in the medical device industry based on PE ratio [1] - As of the first quarter of 2025, 11 institutions hold shares in the company, with a total holding of 266.514 million shares valued at 4.283 billion yuan [1]